Lisen Imprinting Diagnostics has been chosen by Merck as one of the healthcare startups for their 2019 Accelerator Program in China. Lisen initially bested out almost 300 other Asian technology companies to qualify among the 17 startups which were given the opportunity to attend their Accelerator workshop in Shanghai held last October 21-23,2019. Lisen topped the final […]
Read More
Wilmington, DE – Feb 13, 2025 – Lisen Imprinting Diagnostic, Inc. (LisenID) has entered a know-how agreement with Mayo Clinic to research and develop innovative early cancer diagnostic solutions. This collaboration combines LisenID’s epigenetic imprinting technology with Mayo Clinic’s clinical expertise to address gaps in early cancer detection. LisenID specializes in Quantitative Chromogenic Imprinted Gene In-Situ […]
Read More
Lisen Imprinting’s New Technology Eases Fear for HPV-Positive Patients Breakthrough Published in Cancer Communications (IF=20.1): A Novel Early Cervical Cancer Detection Technology Developed by Lisen Imprinting and Sichuan University West China Second University Hospital Wuxi, China – Lisen Imprinting Diagnostics (Wuxi) Co., Ltd. (“Lisen Imprinting”), in collaboration with Sichuan University West China Second University Hospital, has […]
Read More
On November 20, 2024, the final list of winners for the Delaware EDGE (Encouraging Development, Growth & Expansion) competition was announced, with Lisen Imprint among the honorees. The EDGE Award is granted to only 10 businesses per cycle, recognizing the most outstanding and innovative enterprises in Delaware. The EDGE Award was established by the Delaware […]
Read More
Lisen’s invention patent “MODEL, DIAGNOSTIC METHOD, AND APPLICATION THEREOF” about imprinted gene tumor early diagnosis technology was authorized by the European Patent Office on June 22, 2023. Patent number is EP:3633045. The Patent is registered in 17 countries in the Unitary Patent Protection Division, including Germany, France, Italy, Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, Lithuania, Luxembourg, Latvia, Malta, […]
Read MoreLisen announces a revolutionary epigenetics-based diagnostic method for detecting thyroid cancers especially in cytologically indeterminate cases. The clinical research was published in the Journal of Clinical Oncology (JCO), a high-impact, peer-reviewed medical journal of the American Society of Clinical Oncology (ASCO) on November 15. The study leverages Lisen’s QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology which […]
Read More
A press conference and deepening cooperation signing ceremony between Lisen Imprinting and Galixir was held in Shanghai on November 1, 2021. Also present were representatives from Shanghai Zhangjiang Medicine Public Service Platform and Merck China Innovation Center who graced the occasion with congratulatory messages and motivational speeches. Well-known investment institutions such as Baida Finance, BAI […]
Read MoreLisen announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection. The clinical research was published in the Clinical Epigenetics on December 14. The new diagnostic method was based on the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology developed by Lisen, which can intuitively translate the biallelic and multiallelic expression status of cancer-related […]
Read MoreLisen’s methodology paper which innovatively applied visualized epigenetic imprinting biomarkers in the early detection of various cancers has been published in the open access journal Clinical Epigenetics on May 24. Lisen developed and patented the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology – a novel approach in identifying, visualizing, and quantifying the biallelic and multiallelic expressions […]
Read More